scholarly journals Amelioration of tau related pathology with a novel anti‐prion protein monoclonal antibody in an AD mouse model

2021 ◽  
Vol 17 (S9) ◽  
Author(s):  
Allal Boutajangout ◽  
Wei Zhang ◽  
Wed Abdali ◽  
Justin Sung Tae Kim ◽  
Frances Prelli ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Mouse Model ◽  
Prion Protein ◽  
Ad Mouse Model

Intracerebroventricular delivery of dominant negative prion protein in a mouse model of iatrogenic Creutzfeldt-Jakob disease after dura graft transplantation

2006 ◽  
Vol 402 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Kazuhide Furuya ◽  
Nobutaka Kawahara ◽  
Yoshio Yamakawa ◽  
Hitaru Kishida ◽  
Naomi S. Hachiya ◽  
...  
Keyword(s):  
Mouse Model ◽  
Prion Protein ◽  
Dominant Negative ◽  
Jakob Disease

Toward targeted photodynamic therapy

2011 ◽  
Vol 83 (4) ◽  
pp. 733-748 ◽  
Author(s):  
David Phillips
Keyword(s):  
Monoclonal Antibody ◽  
Photodynamic Therapy ◽  
Mouse Model ◽  
Tumor Cells ◽  
Water Solubility ◽  
Human Tumor ◽  
Antibody Fragments ◽  
Cell Kill ◽  
Pyropheophorbide A ◽  
Porphyrin Dimer

The sensitizers in common use for photodynamic therapy (PDT) are summarized, and approaches to the improvement of these outlined. Selectivity in the targeting of sensitizers to tumor cells and tissue is highly desirable, as is water solubility and prevention of aggregation. Some new free sensitizers are described, based upon the pyropheophorbide a (PPa) structure, and their photophysical properties, distribution in cells via confocal fluorescence microscopy, and cell kill properties described. A novel approach to targeting is to covalently attach such sensitizers to monoclonal antibody fragments, and recent work on the attachment of pyropheophorbide a to such monoclonal antibody fragments is reviewed, with a demonstration of the increased efficiency of cell kill, and the treatment of a solid human tumor in a mouse model described. Finally, an alternative method of achieving selectivity based upon two-photon excitation (TPE) using porphyrin dimer sensitizers is reviewed, and the use of these to kill tumor cells is compared with the use of a commercially available PDT sensitizer (Visudyne). TPE of a porphyrin dimer sensitizer is shown to be capable of sealing blood vessels in a mouse model.

scholarly journals Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease

2015 ◽  
Vol 34 (4) ◽  
pp. 2031-2039 ◽  
Author(s):  
XIAOCUI LI ◽  
CUIPING ZHANG ◽  
WEI CHEN ◽  
BIN PAN ◽  
FANYUN KONG ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Mouse Model ◽  
Protective Effect ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

scholarly journals Effect of the Lactococcus Lactis 11/19-B1 Strain on Atopic Dermatitis in a Clinical Test and Mouse Model

Nutrients ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 763 ◽  
Author(s):  
Takato Suzuki ◽  
Kyoko Nishiyama ◽  
Koji Kawata ◽  
Kotaro Sugimoto ◽  
Masato Isome ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Mouse Model ◽  
Lactococcus Lactis ◽  
Skin Lesions ◽  
T Cell Subsets ◽  
Eosinophil Infiltration ◽  
Clinical Test ◽  
Host Immune System ◽  
Cervical Lymph Nodes ◽  
Ad Mouse Model

Some lactic acid bacteria (LAB) are known to improve atopic dermatitis (AD) through the regulation and stimulation of the host immune system. In this study, we found that ingestion of yogurt containing Lactococcus lactis 11/19-B1 strain (L. lactis 11/19-B1) daily for 8 weeks significantly improved the severity scoring of atopic dermatitis (SCORAD) system score from 38.8 ± 14.4 to 24.2 ± 12.0 in children suffering from AD. We tried to identify which LAB species among the five species contained in the test yogurt contributed to the improvement in AD pathology using an AD mouse model induced by repeated application of 1-fluoro-2, 4-dinitrobenzene (DNFB). AD-like skin lesions on the dorsal skin and ear were most improved by L. lactis 11/19-B1 intake among the five LAB species. In addition, analysis of CD4+ T cell subsets in Peyer’s patches (PPs) and cervical lymph nodes (CLNs) indicated that the intake of L. lactis 11/19-B1 generally suppressed all subsets related to inflammation, i.e., Th1, Th2 and Th17, instead of activating the suppressive system, Treg, in the AD mouse model. Histological observations showed ingestion of L. lactis 11/19-B1 significantly suppressed severe inflammatory findings, such as inflammatory cell filtration, epidermal erosion and eosinophil infiltration. These results suggest that the immunomodulatory effects of L. lactis 11/19-B1 contribute to improvements in AD pathology.

Sign in / Sign up

Export Citation Format

Share Document